Validation of a Predictive Nomogram of Response or Resistance to Targeted Therapies in Metastatic Clear Cell Renal Cell Carcinoma

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02848768

Acronym

RTKI

Enrollment

Registered

2016-07-28

Start date

2014-12-01

Completion date

2017-09-21

Last updated

2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic Clear Cell Renal Cell Carcinoma

Brief summary

The purpose of this study is to validate of a predictive nomogram of response or resistance to targeted therapies in metastatic clear cell renal cell carcinoma

Interventions

DRUGSunitinib

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* patients with metastatic ccRCC * Underwent nephrectomy at the University Hospital of Rennes * treated by sunitinib first line treatment

Exclusion criteria

* translocation renal cell carcinoma * other targeted therapies before the sunitinib

Design outcomes

Primary

Measure	Time frame
Primary refractory patients (Progression Free Survival (PFS)	at 3 months

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 23, 2026